Xencor Inc - Asset Resilience Ratio
Xencor Inc (XNCR) has an Asset Resilience Ratio of 50.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check XNCR strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Xencor Inc's Asset Resilience Ratio has changed over time. See XNCR net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Xencor Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Xencor Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $442.75 Million | 50.96% |
| Total Liquid Assets | $442.75 Million | 50.96% |
Asset Resilience Insights
- Very High Liquidity: Xencor Inc maintains exceptional liquid asset reserves at 50.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Xencor Inc Industry Peers by Asset Resilience Ratio
Compare Xencor Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Xencor Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Xencor Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 48.00% | $456.90 Million | $951.95 Million | -8.68pp |
| 2023-12-31 | 56.67% | $539.93 Million | $952.69 Million | -10.58pp |
| 2022-12-31 | 67.25% | $569.12 Million | $846.27 Million | +44.51pp |
| 2021-12-31 | 22.74% | $190.63 Million | $838.21 Million | -39.75pp |
| 2020-12-31 | 62.49% | $439.46 Million | $703.24 Million | -8.64pp |
| 2019-12-31 | 71.13% | $476.77 Million | $670.25 Million | +24.64pp |
| 2018-12-31 | 46.49% | $268.12 Million | $576.73 Million | -6.73pp |
| 2017-12-31 | 53.22% | $207.60 Million | $390.10 Million | +26.24pp |
| 2016-12-31 | 26.98% | $115.61 Million | $428.56 Million | -13.54pp |
| 2015-12-31 | 40.52% | $83.84 Million | $206.91 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $67.82 Million | -- |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more